In Vitro Antifungal Susceptibility of Clinically Relevant Species Belonging to Aspergillus Section Flavi | Zendy

Sarah Santos Gonçalves | Zendy; Alberto M. Stchigel | Zendy; J. Cano | Zendy; Josep Guarro | Zendy; Arnaldo Lopes Colombo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro Antifungal Susceptibility of Clinically Relevant Species Belonging to Aspergillus Section Flavi

Author(s) -

Sarah Santos Gonçalves,

Alberto M. Stchigel,

J. Cano,

Josep Guarro,

Arnaldo Lopes Colombo

Publication year - 2013

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01902-12

Subject(s) - microbiology and biotechnology , antifungal , aspergillus , biology , in vitro , fungi imperfecti , section (typography) , genetics , advertising , business

The in vitro antifungal susceptibility of 77 isolates belonging to different clinically relevant species of Aspergillus section Flavi, including those of different phylogenetic clades of A. flavus, was tested for nine antifungal agents using a microdilution reference method (CLSI, M38-A2). Terbinafine and the echinocandins demonstrated lower MICs/MECs for all species evaluated, followed by posaconazole. Amphotericin B showed MICs ≥ 2 μg/ml for 38 (49.4%) of the 77 isolates tested.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research